Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review

Oliver Warren, Kaushik Mandal, Vassilis Hadjianastassiou, Lisa Knowlton, Sukhmeet Panesar, Kokotsakis John, Ara Darzi, Thanos Athanasiou

Research output: Contribution to journalReview article

Abstract

Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.

Original languageEnglish (US)
Pages (from-to)707-714
Number of pages8
JournalAnnals of Thoracic Surgery
Volume83
Issue number2
DOIs
StatePublished - Feb 1 2007

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Warren, O., Mandal, K., Hadjianastassiou, V., Knowlton, L., Panesar, S., John, K., Darzi, A., & Athanasiou, T. (2007). Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review. Annals of Thoracic Surgery, 83(2), 707-714. https://doi.org/10.1016/j.athoracsur.2006.10.033